KAMADA LTD (KMDA)
IL0010941198 - Common Stock
Kamada Breaks Below 200-Day Moving Average - Notable for KMDA
KMDA Stock Earnings: Kamada Beats EPS, Misses Revenue for Q4 2023
KMDA stock results show that Kamada beat analyst estimates for earnings per share but missed on revenue for the fourth quarter of 2023.
KMDA Stock Earnings: Kamada Beats EPS, Misses Revenue for Q4 2023
InvestorPlace - Stock Market News, Stock Advice & Trading Tips Kamada (NASDAQ:KMDA) just reported results for the fourth quarter of 2023.Kamad...
Kamada Issues 2024 CEO Letter to Shareholders
REHOVOT, Israel, and HOBOKEN, N.J., March 06, 2024 (GLOBE NEWSWIRE) -- Kamada Ltd. (NASDAQ: KMDA; TASE: KMDA.TA), a commercial stage global...
Kamada Reports Strong Fiscal Year and Fourth Quarter 2023 Financial Results, and Provides Full-Year 2024 Guidance Representing Double-Digit Growth in Revenue and Profitability
Total Revenues for Fiscal Year 2023 of $142.5 Million, Representing All-Time Record Annual Revenues and Up 10% Compared to Fiscal Year 2022Fiscal Year 2023...
Kamada to Announce Fourth Quarter and Fiscal Year 2023 Financial Results, and Provide 2024 Financial Guidance on March 6, 2024
Company to Host Conference Call at 8:30am ET
Kamada Announces its Largest Commercial Agreement; A Strategic Engagement with Kedrion for U.S. Distribution of KEDRAB® including $180 Million of Revenues Over First Four Years
Largest Commercial Agreement in Kamada’s History Becomes Effective in January 2024 and Includes $180 Million of Revenues to Kamada Over the First Four...
KMDA Crosses Above Key Moving Average Level
Kamada Reports Significant Increase in Sales and Profitability in the Third Quarter and Nine Month 2023; Reiterates 2023 Revenue and Profitability Guidance
Third Quarter 2023 Revenues were $37.9 Million Representing an 18% Increase Year-over-Year; Nine Month 2023 Revenues of $106.1 Million, Up 26%...
Kamada to Announce Third Quarter and First Nine Months Ended September 30, 2023 Financial Results and Host Conference Call on November 13, 2023
REHOVOT, Israel, and HOBOKEN, N.J., Nov. 08, 2023 (GLOBE NEWSWIRE) -- Kamada Ltd. (NASDAQ & TASE: KMDA), a commercial stage global biopharmaceutical...
Kamada is Now Oversold (KMDA)
Kamada updates on Israel operations (NASDAQ:KMDA)
Israeli biopharmaceutical company Kamada (KMDA) assures no impact on business operations in Israel and uninterrupted global supply of products.
Kamada Provides Corporate Update on its Israel Operations
REHOVOT, Israel, and HOBOKEN, N.J., Oct. 10, 2023 (GLOBE NEWSWIRE) -- Kamada Ltd. (NASDAQ: KMDA; TASE: KMDA.TA), a commercial stage global...
Notable Two Hundred Day Moving Average Cross - KMDA
Kamada files to sell up to $50M of ordinary shares (NASDAQ:KMDA)
Kamada (KMDA) on Monday filed a prospectus to sell up to $50M of ordinary shares.KMDA down 2%.Filing More on Kamada Seeking Alpha’s Quant Rating on Kamada ...
Kamada reports closing of $60M private placement with FIMI opportunity funds (NASDAQ:KMDA)
Kamada (KMDA) Wednesday reported shareholder approval and planned closing of the previously announced $60 million private placement with FIMI Opportunity Funds, the leading private...
Kamada Announces Shareholder Approval and Planned Closing of $60 Million Private Placement with FIMI Opportunity Funds
Funding Strengthens Kamada’s Financial Position, Supporting its Growth Plans and the Pursuit of Strategic Business Development OpportunitiesAppointment of...
Kamada Reports Strong Second Quarter and First Half 2023 Financial Results; Reiterates 2023 Revenue and Profitability Guidance
Second Quarter 2023 Revenues were $37.4 Million, Representing a 59% Increase Year-over-Year; First Half 2023 Revenues of $68.2 Million, Up 32%...
Kamada to Announce Second Quarter and First Half Ended June 30, 2023 Financial Results and Host Conference Call on August 16, 2023
REHOVOT, Israel and HOBOKEN, N.J., Aug. 09, 2023 (GLOBE NEWSWIRE) -- Kamada Ltd. (NASDAQ & TASE: KMDA), a commercial stage global biopharmaceutical...
Kamada Announces Kedrion Exercised its Option for Two-Year Extension of KEDRAB® Distribution Agreement in the U.S.
The Extended Agreement Term is Until March 2026The Company Generated Approximately $16 Million in Revenue from Sales of KEDRAB to Kedrion in 2022 and...
Kamada CFO Chaime Orlev withdraws resignation (NASDAQ:KMDA)
Kamada (KMDA) has announced that Chief Financial Officer (CFO), Chaime Orlev has withdrawn his resignation and will remain in his position.The company raised $60M through private...
Kamada Reports Strong First Quarter 2023 Financial Results; Reiterates Revenue and Profitability Guidance
Total Revenues for First Quarter of 2023 were $30.7 Million, Up 9% Year-over-YearFirst Quarter 2023 EBITDA of $3.8 Million, Increase of 16%...
Kamada Announces Chief Financial Officer Chaime Orlev to Remain in Role and Appointment of Nir Livneh as Vice President, General Counsel and Corporate Secretary
REHOVOT, Israel and HOBOKEN, N.J., May 24, 2023 (GLOBE NEWSWIRE) -- Kamada Ltd. (NASDAQ: KMDA; TASE: KMDA.TA) (“Kamada” or the “Company”), a commercial...
Kamada Announces $60 Million Private Placement with FIMI Opportunity Funds
Funding to Support Kamada’s Growth Plans and Execution of Strategic Business Development Opportunities...
Kamada to Announce First Quarter 2023 Financial Results and Host Conference Call on May 24, 2023
REHOVOT, Israel and HOBOKEN, N.J., May 17, 2023 (GLOBE NEWSWIRE) -- Kamada Ltd. (NASDAQ & TASE: KMDA), a commercial stage global biopharmaceutical...
Kamada Announces Receipt of Marketing Authorization for Glassia® for Treatment of Alpha-1 Antitrypsin Deficiency in Switzerland
Switzerland is the first European country to approve Glassia®, which received U.S. FDA approval in 2010Glassia will be commercialized by IDEOGEN AG in...
Kamada Announces U.S. FDA Approval of its Application to Manufacture CYTOGAM® at the Company’s Facility in Israel
Sales of CYTOGAM® Highest Among Four IgG Products Acquired in November 2021 with Approximately $23 Million in Revenues in 2022, and Gross Margins Over...